{"id":"octreotide-injection","safety":{"commonSideEffects":[{"rate":"15-20","effect":"Abdominal pain"},{"rate":"20-30","effect":"Diarrhea"},{"rate":"10-15","effect":"Nausea"},{"rate":"10-15","effect":"Headache"},{"rate":"5-10","effect":"Hyperglycemia"},{"rate":"15-25","effect":"Gallstone formation (cholelithiasis)"},{"rate":"5-10","effect":"Injection site pain"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Octreotide mimics the action of somatostatin, a natural inhibitory hormone, by binding to somatostatin receptors (particularly SSTR2 and SSTR5) on neuroendocrine cells and blood vessels. This suppresses the release of growth hormone, insulin, glucagon, and other hormones, and reduces splanchnic blood flow. It is used to control symptoms of hormone-secreting tumors and to slow tumor growth in neuroendocrine malignancies.","oneSentence":"Octreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and reduce blood flow to tumors.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:58:03.779Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Acromegaly"},{"name":"Carcinoid syndrome"},{"name":"Variceal bleeding in portal hypertension"},{"name":"Neuroendocrine tumors (gastroenteropancreatic)"},{"name":"Thyroid storm"}]},"trialDetails":[{"nctId":"NCT07255248","phase":"PHASE4","title":"Hoffa's Fat Pad Impingement (HFPI)","status":"RECRUITING","sponsor":"Boston Children's Hospital","startDate":"2026-03-01","conditions":"Hoffa's Fat Pad Impingement","enrollment":62},{"nctId":"NCT07479784","phase":"PHASE3","title":"Octreotide Microspheres for Preventing Pancreatic Fistula","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2026-04-01","conditions":"Pancreatic Fistula","enrollment":230},{"nctId":"NCT06930625","phase":"PHASE3","title":"A Study to Assess the Efficacy and Safety of Debio 4126 in Participants With Acromegaly Previously Treated With Somatostatin Analogs","status":"RECRUITING","sponsor":"Debiopharm International SA","startDate":"2025-11-26","conditions":"Acromegaly","enrollment":119},{"nctId":"NCT03972488","phase":"PHASE3","title":"Study to Evaluate the Efficacy and Safety of Lutathera in Patients With Grade 2 and Grade 3 Advanced GEP-NET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Advanced Accelerator Applications","startDate":"2020-01-08","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor","enrollment":226},{"nctId":"NCT05477576","phase":"PHASE3","title":"Study of RYZ101 Compared With SOC in Pts w Inoperable SSTR+ Well-differentiated GEP-NET That Has Progressed Following 177Lu-SSA Therapy","status":"RECRUITING","sponsor":"RayzeBio, Inc.","startDate":"2022-03-24","conditions":"GEP-NET, Gastroenteropancreatic Neuroendocrine Tumor, Gastroenteropancreatic Neuroendocrine Tumor Disease","enrollment":288},{"nctId":"NCT04125836","phase":"PHASE3","title":"A Trial to Assess the Long-term Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly","status":"COMPLETED","sponsor":"Camurus AB","startDate":"2019-10-10","conditions":"Acromegaly","enrollment":135},{"nctId":"NCT05281328","phase":"PHASE2, PHASE3","title":"A Trial to Assess the Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With PLD","status":"ACTIVE_NOT_RECRUITING","sponsor":"Camurus AB","startDate":"2022-06-28","conditions":"Polycystic Liver Disease","enrollment":71},{"nctId":"NCT05364944","phase":"PHASE1","title":"A Study to Assess the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Debio 4126 in Participants With Acromegaly or Functioning Gastroenteropancreatic Neuroendocrine Tumors (GEP-NETs)","status":"TERMINATED","sponsor":"Debiopharm International SA","startDate":"2022-05-18","conditions":"Acromegaly, GEP-NET","enrollment":19},{"nctId":"NCT05050942","phase":"PHASE3","title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With GEP-NET","status":"ACTIVE_NOT_RECRUITING","sponsor":"Camurus AB","startDate":"2021-10-22","conditions":"Gastro-enteropancreatic Neuroendocrine Tumor","enrollment":332},{"nctId":"NCT06326190","phase":"PHASE2","title":"177Lu-DOTATATE for Recurrent Meningioma","status":"RECRUITING","sponsor":"European Organisation for Research and Treatment of Cancer - EORTC","startDate":"2025-03-10","conditions":"Recurrent Meningioma","enrollment":136},{"nctId":"NCT03000946","phase":"PHASE3","title":"Prevention of Postoperative Pancreatic Fistula by Somatostatin","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2017-05-15","conditions":"Pancreatic Surgery","enrollment":655},{"nctId":"NCT07165886","phase":"PHASE2, PHASE3","title":"Sirolimus for Injection (Albumin Bound) Combined With Octreotide Long-acting Injection in Patients With Metastatic Gastroenteropancreatic Neuroendocrine Tumors","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2025-08-29","conditions":"Gastroenteropancreatic Neuroendocrine Tumors","enrollment":243},{"nctId":"NCT05459844","phase":"PHASE3","title":"A Study Comparing Treatment With Lutetium[177Lu] Oxodotreotide Injection to Octreotide LAR in Patients With GEP-NETs","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sinotau Pharmaceutical Group","startDate":"2022-08-31","conditions":"Neuroendocrine Tumors","enrollment":196},{"nctId":"NCT06345079","phase":"PHASE2","title":"Cessation of Somatostatin Analogues After PRRT in Mid, Hind-Gut and Pancreatic Neuroendocrine Tumours","status":"RECRUITING","sponsor":"Australasian Gastro-Intestinal Trials Group","startDate":"2024-10-14","conditions":"Neuroendocrine Tumors","enrollment":78},{"nctId":"NCT07104487","phase":"PHASE2","title":"[18F]AlF-NOTA-octreotide PET/MRI in Carotid Artery Disease","status":"RECRUITING","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2025-03-18","conditions":"Stroke (CVA) or TIA, Carotid Artery Plaque, Atherosclerosis Cardiovascular Disease","enrollment":24},{"nctId":"NCT07057622","phase":"PHASE3","title":"A Phase III Clinical Study to Compare the Safety and Efficacy of 177Lu-DOTATATE Injection and Long-acting Oxytrexine in Adult Patients With NETs","status":"RECRUITING","sponsor":"HTA Co., Ltd.","startDate":"2023-12-12","conditions":"NETS Ga68 Lu177","enrollment":184},{"nctId":"NCT03049189","phase":"PHASE3","title":"Efficacy and Safety of 177Lu-edotreotide PRRT in GEP-NET Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"ITM Solucin GmbH","startDate":"2017-02-02","conditions":"Neuroendocrine Tumors","enrollment":309},{"nctId":"NCT03289741","phase":"PHASE4","title":"A Study to Evaluate Patient Experience in the Therapy of Neuroendocrine Tumors Treated With Octreotide Long Acting Release Versus Lanreotide","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2017-09-19","conditions":"Neuroendocrine Tumors","enrollment":51},{"nctId":"NCT00113360","phase":"PHASE2","title":"RAD001 Plus Octreotide Depot in Metastatic or Unresectable Low Grade Neuroendocrine Carcinoma","status":"COMPLETED","sponsor":"M.D. Anderson Cancer Center","startDate":"2005-01","conditions":"Neuroendocrine Carcinoma, Islet Cell Carcinoma","enrollment":67},{"nctId":"NCT06881628","phase":"PHASE4","title":"Tranxemic Acid and Vitamin K Injection to Control Upper Gastrointestinal Bleeding in Cirrhotic Patients","status":"RECRUITING","sponsor":"Tanta University","startDate":"2024-12-02","conditions":"Upper Gastrointestinal Bleeding (UGIB), Variceal Bleeding, Cirrhosis","enrollment":194},{"nctId":"NCT06753630","phase":"NA","title":"Polydeoxyribonucleotide for Elbow Lateral Epicondylitis","status":"COMPLETED","sponsor":"Chuncheon Sacred Heart Hospital","startDate":"2014-11-20","conditions":"Lateral Epicondylitis, Extracorporeal Shockwave Therapy, Muscle Strengthening","enrollment":48},{"nctId":"NCT04871204","phase":"PHASE2","title":"Octreotide Treatment to Improve Nutritional Recovery After Surgery for Patients with Esophageal or Gastric Cancer","status":"COMPLETED","sponsor":"Fredrik Klevebro","startDate":"2021-06-16","conditions":"Esophageal Cancer, Gastric Cancer","enrollment":20},{"nctId":"NCT06505395","phase":"PHASE2","title":"A Trial to Assess Efficacy, Safety, Pharmacokinetics of Octreotide Subcutaneous Injection in Patients With Gastroentero-pancreatic Neuroendocrine Tumor (GEP-NET)","status":"RECRUITING","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2024-07-30","conditions":"Gastrointestinal Neuroendocrine Pancreatic Tumor","enrollment":90},{"nctId":"NCT04076462","phase":"PHASE3","title":"A Trial to Assess Efficacy and Safety of Octreotide Subcutaneous Depot in Patients With Acromegaly","status":"COMPLETED","sponsor":"Camurus AB","startDate":"2019-08-19","conditions":"Acromegaly","enrollment":72},{"nctId":"NCT05359146","phase":"EARLY_PHASE1","title":"Combined Beta- Plus Auger Electron Therapy Using a Novel Somatostatin Receptor Subtype 2 Antagonist Labelled With Terbium-161 (161Tb-DOTA-LM3)","status":"RECRUITING","sponsor":"University Hospital, Basel, Switzerland","startDate":"2023-03-28","conditions":"Neuroendocrine Neoplasia's (NENs), Gastroenteropancreatic Neuroendocrine Tumour (GEP-NET)","enrollment":16},{"nctId":"NCT01070758","phase":"PHASE4","title":"Lanreotide Autogel Treatment of Patients With Congenital Hyperinsulinism of Infancy","status":"COMPLETED","sponsor":"Sheba Medical Center","startDate":"2010-02","conditions":"Congenital Hyperinsulinism","enrollment":3},{"nctId":"NCT05749289","phase":"PHASE2, PHASE3","title":"Application of Al18F-octreotide PET/CT in Neuroendocrine Tumor","status":"RECRUITING","sponsor":"Cancer Institute and Hospital, Chinese Academy of Medical Sciences","startDate":"2022-12-20","conditions":"Neuroendocrine Tumor","enrollment":400},{"nctId":"NCT06254235","phase":"PHASE1","title":"Bioequivalence Study of Two Octreotide Microsphere Formulations in Healthy Volunteers","status":"COMPLETED","sponsor":"Qilu Pharmaceutical Co., Ltd.","startDate":"2021-06-16","conditions":"Healthy Volunteers","enrollment":240},{"nctId":"NCT03724409","phase":"EARLY_PHASE1","title":"Selective Intra-arterial Injection of PRRT in Neuroendocrine Tumor Patients With Liver Metastases","status":"TERMINATED","sponsor":"Sandeep Laroia","startDate":"2018-10-11","conditions":"Neuroendocrine Tumors","enrollment":3},{"nctId":"NCT06080204","phase":"NA","title":"Real-world Study on Adjuvant Octreotide Therapy in pNETs","status":"COMPLETED","sponsor":"Changhai Hospital","startDate":"2008-03","conditions":"Pancreatic Neuroendocrine Tumor G2","enrollment":411},{"nctId":"NCT05761431","phase":"PHASE1","title":"A Single-dose Study of Octreotide Injection in Healthy Adult Subjects","status":"COMPLETED","sponsor":"CSPC ZhongQi Pharmaceutical Technology Co., Ltd.","startDate":"2023-03-02","conditions":"Acromegaly","enrollment":56},{"nctId":"NCT05884255","phase":"PHASE3","title":"An Open-label Phase 3 Study of Lutetium (177Lu) Oxodotreotide Injection in Subjects With Advanced Gastrointestinal Pancreatic Neuroendocrine Tumors.","status":"RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-07-06","conditions":"Advanced Gastroenteropancreatic Neuroendocrine Tumor","enrollment":220},{"nctId":"NCT00427349","phase":"PHASE2","title":"AMG 706 and Octreotide in Treating Patients With Low-Grade Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Eastern Cooperative Oncology Group","startDate":"2008-11-07","conditions":"Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Neoplastic Syndrome","enrollment":46},{"nctId":"NCT05894486","phase":"PHASE2","title":"Phase II Study to Evaluate the Efficacy and Safety of 177Lu-Dotatate in the First-line Treatment of Patients With Locally Advanced or Metastatic, Somatostatin Receptor-positive G2 or G3 Gastroenteropancreatic Neuroendocrine Tumors","status":"NOT_YET_RECRUITING","sponsor":"Peking University","startDate":"2023-06-05","conditions":"Neuroendocrine Tumors","enrollment":40},{"nctId":"NCT02384122","phase":"PHASE3","title":"Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias","status":"COMPLETED","sponsor":"Radboud University Medical Center","startDate":"2015-09","conditions":"Angiodysplasia, Vascular Malformations, Gastrointestinal Hemorrhage","enrollment":62},{"nctId":"NCT03967249","phase":"PHASE2","title":"Extension Study of IONIS-GHR-LRx Administered to Participants With Acromegaly Being Treated With Long-acting Somatostatin Receptor Ligands","status":"COMPLETED","sponsor":"Ionis Pharmaceuticals, Inc.","startDate":"2019-07-25","conditions":"Acromegaly","enrollment":39},{"nctId":"NCT02335580","phase":"","title":"Effect of Portal Vein Thrombosis on the Prognosis of Liver Cirrhosis","status":"COMPLETED","sponsor":"General Hospital of Shenyang Military Region","startDate":"2014-12","conditions":"Liver Cirrhosis, Portal Vein, Venous Thrombosis","enrollment":475},{"nctId":"NCT03273712","phase":"PHASE2","title":"Dosimetry-Guided, Peptide Receptor Radiotherapy (PRRT) With 90Y-DOTA- tyr3-Octreotide (90Y-DOTATOC)","status":"COMPLETED","sponsor":"University of Iowa","startDate":"2017-09-29","conditions":"Neuroendocrine Tumors, Meningioma, Neuroblastoma","enrollment":39},{"nctId":"NCT03891849","phase":"NA","title":"Macro and Microcirculatory Effects of the Combination of Norepinephrine and Octreotide for the Treatment of Cirrhotic Patients With Hemorrhagic Shock","status":"WITHDRAWN","sponsor":"Centre Hospitalier Universitaire, Amiens","startDate":"2021-09-01","conditions":"Haemorrhagic Shock, Variceal Hemorrhage","enrollment":""},{"nctId":"NCT05682209","phase":"PHASE4","title":"The Effect of Octreotide on Wound Drainage After Mastectomy","status":"COMPLETED","sponsor":"Ikechukwu Bartholomew Ulasi","startDate":"2020-12-18","conditions":"Seroma Following Procedure","enrollment":41},{"nctId":"NCT01613495","phase":"NA","title":"Ghrelin Suppression by Octreotide in Prader-Willi","status":"UNKNOWN","sponsor":"Oregon Health and Science University","startDate":"2005-08","conditions":"Prader Willis Syndrome","enrollment":2},{"nctId":"NCT03541447","phase":"PHASE2","title":"Tolvaptan-Octreotide LAR Combination in ADPKD","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2018-12-12","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":20},{"nctId":"NCT03791736","phase":"NA","title":"Evaluation of Impact of Sandostatin® Injection Before Axillary Clearance on Lymphocele Formation","status":"TERMINATED","sponsor":"Institut Cancerologie de l'Ouest","startDate":"2016-07-06","conditions":"Breast Cancer, Lymphocele","enrollment":4},{"nctId":"NCT02010385","phase":"NA","title":"Investigation of the Effects of Obesity Surgery on Appetitive Behaviour","status":"COMPLETED","sponsor":"University College Dublin","startDate":"2013-02","conditions":"Roux-en-Y Bariatric Surgery","enrollment":30},{"nctId":"NCT02685709","phase":"PHASE3","title":"Comparison of Oral Octreotide Capsules to Injectable Somatostatin Analogs in Acromegaly","status":"COMPLETED","sponsor":"Chiasma, Inc.","startDate":"2016-02","conditions":"Acromegaly","enrollment":146},{"nctId":"NCT01578239","phase":"PHASE3","title":"A Study Comparing Treatment With 177Lu-DOTA0-Tyr3-Octreotate to Octreotide LAR in Patients With Inoperable, Progressive, Somatostatin Receptor Positive Midgut Carcinoid Tumours","status":"COMPLETED","sponsor":"Advanced Accelerator Applications","startDate":"2012-09-06","conditions":"Carcinoid Tumor of the Small Bowel, Neuroendocrine Tumour","enrollment":231},{"nctId":"NCT04552847","phase":"PHASE2, PHASE3","title":"Al18F-NOTA-octreotide PET Imaging in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2020-10-07","conditions":"Neuroendocrine Tumors","enrollment":85},{"nctId":"NCT05171751","phase":"","title":"Efficacy and Safety Evaluation of Octreotide in the Treatment of Congenital Hyperinsulinemia","status":"COMPLETED","sponsor":"Beijing Children's Hospital","startDate":"2021-11-01","conditions":"Congenital Hyperinsulinaemic Hypoglycaemia, Octreotide Adverse Reaction","enrollment":50},{"nctId":"NCT00171730","phase":"PHASE2","title":"An Extension Study to Assess the Long-Term Safety and Efficacy of Pasireotide in Participants With Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2004-08-24","conditions":"Acromegaly","enrollment":30},{"nctId":"NCT03734627","phase":"","title":"Gastrointestinal Nutrient Transit and Enteroendocrine Function After Upper Gastrointestinal Surgery","status":"COMPLETED","sponsor":"St. James's Hospital, Ireland","startDate":"2016-07-01","conditions":"Esophageal Cancer, Nutrition Disorders, Appetite Disorders","enrollment":40},{"nctId":"NCT01789281","phase":"PHASE4","title":"Everolimus Roll-over Protocol for Patients Who Have Completed a Previous Novartis-sponsored Everolimus Study.","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2013-05-14","conditions":"Neoplasms","enrollment":34},{"nctId":"NCT01744249","phase":"PHASE2, PHASE3","title":"Sandostatin LAR and Axitinib vs Pbo in Pnts With Advanced Well-differentiated Non-pancreatic Neuroendocrine Carcinomas","status":"UNKNOWN","sponsor":"Grupo Espanol de Tumores Neuroendocrinos","startDate":"2011-11","conditions":"Neuroendocrine Tumors, Advanced Cancer","enrollment":255},{"nctId":"NCT03252353","phase":"PHASE3","title":"Efficacy and Safety of Octreotide Capsules (MYCAPSSA) in Acromegaly","status":"UNKNOWN","sponsor":"Chiasma, Inc.","startDate":"2017-09-01","conditions":"Acromegaly","enrollment":56},{"nctId":"NCT03883776","phase":"PHASE1","title":"Al18F-NOTA-octreotide PET Imaging of the Somatostatin Receptor in Neuroendocrine Tumors","status":"COMPLETED","sponsor":"Universitaire Ziekenhuizen KU Leuven","startDate":"2019-04-11","conditions":"Neuroendocrine Tumors","enrollment":12},{"nctId":"NCT04522297","phase":"NA","title":"Nor-epinephrine Versus Midodrine/Octreotide in Patients With Hepatorenal Syndrome","status":"COMPLETED","sponsor":"National Hepatology & Tropical Medicine Research Institute","startDate":"2018-04-15","conditions":"Hepato-Renal Syndrome","enrollment":91},{"nctId":"NCT00092287","phase":"PHASE3","title":"Comparison of Lanreotide Autogel® and Sandostatin LAR Depot in the Treatment of Clinical Symptoms Associated With Carcinoid Syndrome","status":"TERMINATED","sponsor":"Ipsen","startDate":"2004-07","conditions":"Malignant Carcinoid Syndrome","enrollment":4},{"nctId":"NCT00002864","phase":"PHASE3","title":"Tamoxifen With or Without Octreotide in Treating Postmenopausal Women With Stage I, Stage II, or Stage III Breast Cancer","status":"COMPLETED","sponsor":"NCIC Clinical Trials Group","startDate":"1996-09-24","conditions":"Breast Cancer","enrollment":667},{"nctId":"NCT00444873","phase":"PHASE3","title":"Effect of 120mg Somatuline Autogel at Different Dose Intervals (28, 42 or 56 Days) in Patients With Acromegaly","status":"COMPLETED","sponsor":"Ipsen","startDate":"2005-01","conditions":"Acromegaly","enrollment":38},{"nctId":"NCT04140409","phase":"PHASE4","title":"Sandostatin (Octreotide LAR) May Lead to Clinical Improvement Through Receptor Occupation Optimisation","status":"TERMINATED","sponsor":"Cliniques universitaires Saint-Luc- Université Catholique de Louvain","startDate":"2016-02-02","conditions":"Neuroendocrine Tumors, Carcinoid Syndrome","enrollment":10},{"nctId":"NCT02294786","phase":"PHASE2","title":"Study of Prophylactic Octreotide to Prevent or Reduce the Frequency and Severity of Diarrhoea in Subjects Receiving Lapatinib With Capecitabine for the Treatment of Metastatic Breast Cancer","status":"TERMINATED","sponsor":"Novartis Pharmaceuticals","startDate":"2014-12-17","conditions":"Cancer","enrollment":62},{"nctId":"NCT02396953","phase":"PHASE1, PHASE2","title":"Study to Determine the Maximum Tolerated Dose, Safety and Tolerability of a Single Dose of Lanreotide Prolonged Release Formulation (PRF) in Subjects With Acromegaly","status":"COMPLETED","sponsor":"Ipsen","startDate":"2015-03","conditions":"Acromegaly","enrollment":28},{"nctId":"NCT01587222","phase":"PHASE2","title":"Midodrine, Octreotide and Albumin: Impact on Renal Function of Patients With Liver Cirrhosis and Renal Failure","status":"WITHDRAWN","sponsor":"Anna Cruceta","startDate":"2016-07","conditions":"Fibrosis, Renal Failure, Hepatorenal Syndrome","enrollment":""},{"nctId":"NCT00701363","phase":"PHASE4","title":"Study to Assess the Efficacy of an Extended Injection Interval Schedule of Lanreotide Autogel in Acromegalic Subjects","status":"COMPLETED","sponsor":"Ipsen","startDate":"2008-10","conditions":"Acromegaly","enrollment":124},{"nctId":"NCT03812939","phase":"","title":"Recurrence Rates of Type I Gastric Neuroendocrine Tumors Treated With Long-acting Somatostatin Analogs","status":"UNKNOWN","sponsor":"Peking Union Medical College Hospital","startDate":"2019-01-01","conditions":"Gastric NET","enrollment":30},{"nctId":"NCT00552071","phase":"PHASE4","title":"Ultrasound Guided Octreotide LAR Injection in Acromegaly","status":"COMPLETED","sponsor":"Cedars-Sinai Medical Center","startDate":"2007-07","conditions":"Acromegaly","enrollment":15},{"nctId":"NCT03511768","phase":"PHASE1, PHASE2","title":"A Study of 18F-AlF-NOTA-octreotide PET/CT for Imaging Neuroendocrine Neoplasms","status":"UNKNOWN","sponsor":"Xiangya Hospital of Central South University","startDate":"2018-01-02","conditions":"Neuroendocrine Neoplasm","enrollment":65},{"nctId":"NCT02874326","phase":"PHASE2","title":"Octreotide in Patients With GI Bleeding Due to Rendu-Osler-Weber","status":"UNKNOWN","sponsor":"Radboud University Medical Center","startDate":"2016-10","conditions":"Hereditary Hemorrhagic Telangiectasia, Gastrointestinal Hemorrhage, Anemia","enrollment":15},{"nctId":"NCT01137682","phase":"PHASE3","title":"Efficacy and Safety of Pasireotide Long Acting Release (LAR) Versus Octreotide LAR or Lanreotide Autogel (ATG) in Patients With Inadequately Controlled Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2010-07-19","conditions":"Acromegaly","enrollment":198},{"nctId":"NCT02217800","phase":"PHASE2","title":"The Effect of Subcutaneous Infusions of 3 Doses of DG3173 on Growth Hormone Levels in Untreated Acromegalics","status":"COMPLETED","sponsor":"Aspireo Pharmaceuticals Limited","startDate":"2013-11","conditions":"Acromegaly","enrollment":8},{"nctId":"NCT02235987","phase":"PHASE2","title":"Single Dose Pharmacology Study of DG3173 and Octreotide in Acromegalic Patients.","status":"COMPLETED","sponsor":"Aspireo Pharmaceuticals Limited","startDate":"2012-10","conditions":"Acromegaly","enrollment":20},{"nctId":"NCT01377246","phase":"PHASE3","title":"Somatostatin In Patients With Autosomal Dominant Polycystic Kidney Disease And Moderate To Severe Renal Insufficiency","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2011-05","conditions":"Autosomal Dominant Polycystic Kidney Disease","enrollment":100},{"nctId":"NCT02299089","phase":"PHASE2","title":"Phase II Study of Subcutaneous Inj. Depot of Octreotide in Patients With Acromegaly and Neuroendocrine Tumours (NETs)","status":"COMPLETED","sponsor":"Camurus AB","startDate":"2015-01","conditions":"Acromegaly, Neuroendocrine Tumors","enrollment":12},{"nctId":"NCT03013387","phase":"PHASE2","title":"Dosimetry Guided PRRT With 90Y-DOTATOC","status":"WITHDRAWN","sponsor":"Sue O'Dorisio","startDate":"2017-01","conditions":"Neuroendrocrine Tumors, Meningioma, Neuroblastoma","enrollment":""},{"nctId":"NCT00600886","phase":"PHASE3","title":"Safety and Efficacy of Pasireotide Long Acting Release (LAR) vs. Octreotide LAR in Patients With Active Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-02-11","conditions":"Acromegaly","enrollment":358},{"nctId":"NCT03031535","phase":"PHASE1","title":"Study of Intranasal Octreotide (DP1038) in Healthy Adult Volunteers","status":"COMPLETED","sponsor":"Dauntless Pharmaceuticals","startDate":"2017-01","conditions":"Healthy Volunteer Study","enrollment":32},{"nctId":"NCT02374632","phase":"PHASE4","title":"Gut Hormones as Mediators of Different Weight Loss Responses After Roux-en-Y Gastric Bypass","status":"UNKNOWN","sponsor":"Hvidovre University Hospital","startDate":"2014-10","conditions":"Bariatric Surgery (Gastric Bypass), Severe Obesity","enrollment":40},{"nctId":"NCT01707225","phase":"PHASE1","title":"Safety Study of Octreotide Injection to Prevent GI Bleeding in Patients With Left Ventricular Assist Device (LVAD)","status":"COMPLETED","sponsor":"Virginia Commonwealth University","startDate":"2013-02","conditions":"Gastrointestinal Bleeding","enrollment":10},{"nctId":"NCT02668588","phase":"PHASE2","title":"Extended-release of Octreotide (LF-PB) for the Treatment of Seroma","status":"COMPLETED","sponsor":"Chemi S.p.A.","startDate":"2015-10-22","conditions":"Seroma","enrollment":48},{"nctId":"NCT01618513","phase":"PHASE4","title":"Treatment of Acromegaly With Somatostatin Analogs: GH vs. IGF-I as Primary Biochemical Target","status":"COMPLETED","sponsor":"University of Aarhus","startDate":"2012-06","conditions":"Acromegaly","enrollment":84},{"nctId":"NCT02195635","phase":"PHASE1","title":"Phase 1, Open-label, Drug-drug Interaction Study With Octreotide Acetate Injection and Telotristat Etiprate in Healthy Subjects","status":"COMPLETED","sponsor":"Lexicon Pharmaceuticals","startDate":"2014-07","conditions":"Drug Interactions","enrollment":24},{"nctId":"NCT02119884","phase":"PHASE4","title":"Hemodynamic Effects of Terlipressin and High Dose Octreotide","status":"COMPLETED","sponsor":"Shanghai Zhongshan Hospital","startDate":"2014-02","conditions":"Gastric and Esophageal Varices","enrollment":88},{"nctId":"NCT01860742","phase":"PHASE3","title":"Randomized Phase III of PRRT Versus Interferon","status":"WITHDRAWN","sponsor":"Jules Bordet Institute","startDate":"2014-12","conditions":"Gastro-intestinal Neuroendocrine Tumors","enrollment":""},{"nctId":"NCT01121939","phase":"PHASE2","title":"Combination of Bevacizumab, Pertuzumab, and Sandostatin for Adv. Neuroendocrine Cancers","status":"COMPLETED","sponsor":"SCRI Development Innovations, LLC","startDate":"2010-05","conditions":"Neuroendocrine Carcinoma","enrollment":43},{"nctId":"NCT02631616","phase":"PHASE1","title":"Treatment With Sandostatin in Patients With Castrate Resistance Prostate Cancer Showing Uptake of 68Ga-DOTATET","status":"UNKNOWN","sponsor":"Hadassah Medical Organization","startDate":"2016-02","conditions":"Prostatic Neoplasms","enrollment":30},{"nctId":"NCT02012166","phase":"PHASE1","title":"A Study of MK-0893 on Glucagon-Induced Glycemic Excursion in Healthy Male Participants Following Intravenous Administration of Glucagon, Sandostatine® and Insulin (MK-0893-002)","status":"COMPLETED","sponsor":"Merck Sharp & Dohme LLC","startDate":"2005-07","conditions":"Type 2 Diabetes Mellitus","enrollment":18},{"nctId":"NCT00978211","phase":"PHASE2","title":"DOTA-TOC in Metastasized Neuroendocrine Tumors","status":"COMPLETED","sponsor":"University Hospital, Basel, Switzerland","startDate":"1997-09","conditions":"Neuroendocrine Tumors","enrollment":1499},{"nctId":"NCT02427295","phase":"PHASE4","title":"Hormonal Outcomes in Acromegalic Patients With Treated Surgery With or Without Long Acting Somatostatin Analogues","status":"UNKNOWN","sponsor":"Asan Medical Center","startDate":"2014-03","conditions":"Acromegaly","enrollment":1},{"nctId":"NCT02311608","phase":"","title":"Effects of Terlipressin When Usual Somatostatin or Octreotide Dose Fails","status":"UNKNOWN","sponsor":"Shanghai Zhongshan Hospital","startDate":"2014-02","conditions":"Liver Cirrhosis, Esophageal and Gastric Varices, Hemorrhage","enrollment":1320},{"nctId":"NCT01754285","phase":"PHASE2","title":"Extended-release of Octreotide (LF-PB) for the Treatment of Lymphorrhea","status":"COMPLETED","sponsor":"Chemi S.p.A.","startDate":"2012-11","conditions":"Lymphorrhea","enrollment":114},{"nctId":"NCT00399893","phase":"NA","title":"Octreotide Therapy in Children and Young Adults With Prader-Willi Syndrome (PWS)","status":"TERMINATED","sponsor":"Duke University","startDate":"2006-12","conditions":"Prader-Willi Syndrome","enrollment":5},{"nctId":"NCT00108355","phase":"PHASE4","title":"Vasoconstrictors as Alternatives to Albumin After Large-Volume Paracentesis (LVP) in Cirrhosis","status":"COMPLETED","sponsor":"US Department of Veterans Affairs","startDate":"2003-12","conditions":"Ascites, Cirrhosis","enrollment":29},{"nctId":"NCT00987168","phase":"PHASE2","title":"Sandostatine® LP and Hyperinsulinism","status":"COMPLETED","sponsor":"Assistance Publique - Hôpitaux de Paris","startDate":"2009-05","conditions":"Congenital Hyperinsulinism","enrollment":10},{"nctId":"NCT00765323","phase":"PHASE3","title":"Efficacy and Safety Study of Octreotide Implant in Patients With Acromegaly","status":"TERMINATED","sponsor":"Endo Pharmaceuticals","startDate":"2008-09","conditions":"Acromegaly","enrollment":169},{"nctId":"NCT00690430","phase":"PHASE3","title":"Efficacy and Safety of Pasireotide Long Acting Release vs. Octreotide Long Acting Release in Patients With Metastatic Carcinoid Disease","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2008-04","conditions":"Symptomatic Refractory Resistant Carcinoid Disease","enrollment":186},{"nctId":"NCT00309283","phase":"PHASE3","title":"Somatostatin in Polycystic Kidney: a Long-term Three Year Follow up Study","status":"COMPLETED","sponsor":"Mario Negri Institute for Pharmacological Research","startDate":"2006-04","conditions":"Autosomal Dominant Polycystic Kidney Disease (ADPKD)","enrollment":78},{"nctId":"NCT01561066","phase":"PHASE1","title":"Autologous Fibrin Glues for Fistulas Closure","status":"COMPLETED","sponsor":"Jinling Hospital, China","startDate":"2008-01","conditions":"Enterocutaneous Fistulas, Intra-abdominal Infection","enrollment":122},{"nctId":"NCT00426153","phase":"PHASE2, PHASE3","title":"Octreotide in Severe Polycystic Liver Disease","status":"COMPLETED","sponsor":"Mayo Clinic","startDate":"2007-01","conditions":"Polycystic Kidney, Autosomal Dominant, Polycystic Liver Disease, Hepatomegaly","enrollment":42},{"nctId":"NCT00225979","phase":"PHASE3","title":"Safety and Efficacy of Long-acting Repeatable Octreotide Acetate for Injectable Suspension vs. Surgery in Treatment-naïve Patients With Acromegaly","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2002-11","conditions":"Acromegaly","enrollment":100},{"nctId":"NCT01400100","phase":"NA","title":"Effects of Intraarterial Octreotide on Pancreatic Texture","status":"COMPLETED","sponsor":"St. Josef Hospital Bochum","startDate":"2011-08","conditions":"Pancreatic Fistula","enrollment":26},{"nctId":"NCT00332696","phase":"PHASE2","title":"Octreotide Compared to Placebo in Patients With Inoperable Bowel Obstruction Due to Peritoneal Carcinomatosis","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2005-09","conditions":"Peritoneal Neoplasms, Intestinal Obstruction, Carcinomatosis","enrollment":64}],"_emaApprovals":[],"_faersSignals":[{"count":6,"reaction":"PRODUCT USE IN UNAPPROVED INDICATION"},{"count":5,"reaction":"DIARRHOEA"},{"count":5,"reaction":"PRODUCT USE ISSUE"},{"count":3,"reaction":"DEATH"},{"count":3,"reaction":"DRUG INEFFECTIVE FOR UNAPPROVED INDICATION"},{"count":3,"reaction":"HYPERHIDROSIS"},{"count":3,"reaction":"INAPPROPRIATE SCHEDULE OF DRUG ADMINISTRATION"},{"count":3,"reaction":"MALIGNANT NEOPLASM PROGRESSION"},{"count":3,"reaction":"MULTI-ORGAN FAILURE"},{"count":3,"reaction":"NECROTISING COLITIS"}],"_approvalHistory":[],"publicationCount":78,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Actide, Samarth, India","glucose"],"phase":"marketed","status":"active","brandName":"Octreotide Injection","genericName":"Octreotide Injection","companyName":"Centre Hospitalier Universitaire, Amiens","companyId":"centre-hospitalier-universitaire-amiens","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Octreotide is a somatostatin analog that binds to somatostatin receptors to inhibit the secretion of various hormones and gastrointestinal peptides. Used for Acromegaly, Variceal bleeding in portal hypertension, Neuroendocrine tumors (carcinoid syndrome, VIPomas).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}